Rhythm Pharmaceuticals Announces New Employment Inducement Grants
16 sept. 2024 16h01 HE
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...
Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old
26 août 2024 08h02 HE
|
Rhythm Pharmaceuticals, Inc.
-- Label expansion sought to treat younger children with Bardet-Biedl syndrome or POMC/LEPR deficiency -- -- FDA sets PDUFA goal date of December 26, 2024 -- BOSTON, Aug. 26, 2024 ...
Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September
26 août 2024 08h00 HE
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
13 août 2024 16h01 HE
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update
06 août 2024 07h00 HE
|
Rhythm Pharmaceuticals, Inc.
-- Second quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $29.1 million -- -- Dosed first patients in supplemental, 12-patient Japanese cohort in global Phase 3 trial...
Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old
31 juil. 2024 09h10 HE
|
Rhythm Pharmaceuticals, Inc.
BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their...
Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity
23 juil. 2024 08h00 HE
|
Rhythm Pharmaceuticals, Inc.
-- LB54640 has shown targeted effect on MC4R without hyperpigmentation -- BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical...
Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
23 juil. 2024 07h30 HE
|
Rhythm Pharmaceuticals, Inc.
BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
11 juil. 2024 16h01 HE
|
Rhythm Pharmaceuticals, Inc.
BOSTON, July 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer
08 juil. 2024 08h00 HE
|
Rhythm Pharmaceuticals, Inc.
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...